{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cortez NE"],"funding":["HHS | NIH | National Cancer Institute","NCI NIH HHS","USDA | National Institute of Food and Agriculture"],"pagination":["951-965"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9648418"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2(9)"],"pubmed_abstract":["Pancreatic ductal adenocarcinoma (PDAC) continues to be a major health problem. A ketogenic diet (KD), characterized by a very low carbohydrate and high fat composition, has gained attention for its anti-tumor potential. We evaluated the effect and mechanisms of feeding a strict KD alone or in combination with gemcitabine in the autochthonous LSL-Kras<sup>G12D/+</sup>; LSL-Trp53 <sup>R172H/+</sup>; Pdx1-Cre (KPC) mouse model. For this purpose, both male and female pancreatic tumor-bearing KPC mice were allocated to a control diet (CD; %kcal: 70% carb, 14% protein, 16% fat), a KD (%kcal: 14% protein, 1% carb, 85% fat), a CD + gemcitabine (CG), or a KD + gemcitabine (KG) group. Mice fed a KD alone or in combination with gemcitabine showed significantly increased blood β-hydroxybutyrate level"],"journal":["Cancer research communications"],"pubmed_title":["A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice."],"pmcid":["PMC9648418"],"funding_grant_id":["CA-D-NTR-2397-H","P30CA093373","P30 CA093373"],"pubmed_authors":["Muller M","Hwang CI","Pontifex MG","Wang F","Vauzour D","Rodriguez Lanzi C","Xu J","Mackenzie GG","Matsukuma K","Hong BV","Chen S","Vahmani P","Cortez NE","Ramsey JJ"],"additional_accession":[]},"is_claimable":false,"name":"A ketogenic diet in combination with gemcitabine increases survival in pancreatic cancer KPC mice.","description":"Pancreatic ductal adenocarcinoma (PDAC) continues to be a major health problem. A ketogenic diet (KD), characterized by a very low carbohydrate and high fat composition, has gained attention for its anti-tumor potential. We evaluated the effect and mechanisms of feeding a strict KD alone or in combination with gemcitabine in the autochthonous LSL-Kras<sup>G12D/+</sup>; LSL-Trp53 <sup>R172H/+</sup>; Pdx1-Cre (KPC) mouse model. For this purpose, both male and female pancreatic tumor-bearing KPC mice were allocated to a control diet (CD; %kcal: 70% carb, 14% protein, 16% fat), a KD (%kcal: 14% protein, 1% carb, 85% fat), a CD + gemcitabine (CG), or a KD + gemcitabine (KG) group. Mice fed a KD alone or in combination with gemcitabine showed significantly increased blood β-hydroxybutyrate level","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-05-10T06:13:12.021Z","creation":"2025-04-19T12:10:45.177Z"},"accession":"S-EPMC9648418","cross_references":{"pubmed":["36382086"],"doi":["10.1158/2767-9764.crc-22-0256"]}}